Olga Kantor1,2,3, Anna Weiss1,2,3, Harold J Burstein2,3,4, Elizabeth A Mittendorf1,2,3, Tari A King5,6,7. 1. Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA. 2. Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA. 3. Harvard Medical School, Boston, MA, USA. 4. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 5. Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA. tking7@bwh.harvard.edu. 6. Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA. tking7@bwh.harvard.edu. 7. Harvard Medical School, Boston, MA, USA. tking7@bwh.harvard.edu.
Abstract
BACKGROUND: The RxPONDER trial randomized patients with cT1-3N0 hormone receptor-positive, HER2-negative (HR+HER2-) breast cancer and one to three positive nodes and Recurrence Score (RS) < 26 to endocrine therapy (ET) or chemoendocrine therapy (CET) with equivalent survival in postmenopausal women. In current practice, cN0 patients with one or two positive sentinel lymph nodes (SLN) do not undergo axillary lymph node dissection (ALND), raising concerns about applying these data in patients who may have additional nodal disease. METHODS: We identified institutional [Dana-Farber Brigham Cancer Center (DF/BCC), 2016-2020] and national [National Cancer Database (NCDB), 2012-2017] cohorts of women aged 50-75 years with cT1-3N0 HR+HER2- breast cancer and RS < 26 treated with upfront surgery with one to three positive SLN. Axillary nodal burden and outcomes were assessed on the basis of the number of positive nodes and CET use. RESULTS: A total of 197 and 13,499 HR+HER2- eligible patients with one to three positive SLN and RS < 26 were identified in the DF/BCC and NCDB databases, respectively, and 12.7% of DF/BCC and 32.4% of NCDB patients had ALND. Of these, only 12.0 and 4.9% had more than three total positive nodes, respectively. Rates of CET were 6.6% in DF/BCC and 20.9% in NCDB patients. In the NCDB, similar adjusted 4-year overall survival was seen between patients treated with CET or ET for any number of positive nodes (98.1-99.9%, all p > 0.05). CONCLUSIONS: Postmenopausal women with cT1-3N0 HR+HER2- breast cancer and RS < 26 with one to three positive SLN are unlikely to have more than three total positive nodes. CET decisions should continue to be based on SLN biopsy as ALND is unlikely to change treatment recommendations or outcomes.
BACKGROUND: The RxPONDER trial randomized patients with cT1-3N0 hormone receptor-positive, HER2-negative (HR+HER2-) breast cancer and one to three positive nodes and Recurrence Score (RS) < 26 to endocrine therapy (ET) or chemoendocrine therapy (CET) with equivalent survival in postmenopausal women. In current practice, cN0 patients with one or two positive sentinel lymph nodes (SLN) do not undergo axillary lymph node dissection (ALND), raising concerns about applying these data in patients who may have additional nodal disease. METHODS: We identified institutional [Dana-Farber Brigham Cancer Center (DF/BCC), 2016-2020] and national [National Cancer Database (NCDB), 2012-2017] cohorts of women aged 50-75 years with cT1-3N0 HR+HER2- breast cancer and RS < 26 treated with upfront surgery with one to three positive SLN. Axillary nodal burden and outcomes were assessed on the basis of the number of positive nodes and CET use. RESULTS: A total of 197 and 13,499 HR+HER2- eligible patients with one to three positive SLN and RS < 26 were identified in the DF/BCC and NCDB databases, respectively, and 12.7% of DF/BCC and 32.4% of NCDB patients had ALND. Of these, only 12.0 and 4.9% had more than three total positive nodes, respectively. Rates of CET were 6.6% in DF/BCC and 20.9% in NCDB patients. In the NCDB, similar adjusted 4-year overall survival was seen between patients treated with CET or ET for any number of positive nodes (98.1-99.9%, all p > 0.05). CONCLUSIONS: Postmenopausal women with cT1-3N0 HR+HER2- breast cancer and RS < 26 with one to three positive SLN are unlikely to have more than three total positive nodes. CET decisions should continue to be based on SLN biopsy as ALND is unlikely to change treatment recommendations or outcomes.
Authors: Gong Tang; Steven Shak; Soonmyung Paik; Stewart J Anderson; Joseph P Costantino; Charles E Geyer; Eleftherios P Mamounas; D Lawrence Wickerham; Norman Wolmark Journal: Breast Cancer Res Treat Date: 2011-01-11 Impact factor: 4.872
Authors: Mila Donker; Geertjan van Tienhoven; Marieke E Straver; Philip Meijnen; Cornelis J H van de Velde; Robert E Mansel; Luigi Cataliotti; A Helen Westenberg; Jean H G Klinkenbijl; Lorenzo Orzalesi; Willem H Bouma; Huub C J van der Mijle; Grard A P Nieuwenhuijzen; Sanne C Veltkamp; Leen Slaets; Nicole J Duez; Peter W de Graaf; Thijs van Dalen; Andreas Marinelli; Herman Rijna; Marko Snoj; Nigel J Bundred; Jos W S Merkus; Yazid Belkacemi; Patrick Petignat; Dominic A X Schinagl; Corneel Coens; Carlo G M Messina; Jan Bogaerts; Emiel J T Rutgers Journal: Lancet Oncol Date: 2014-10-15 Impact factor: 41.316
Authors: Monica Morrow; Kimberly J Van Zee; Sujata Patil; Oriana Petruolo; Anita Mamtani; Andrea V Barrio; Deborah Capko; Mahmoud El-Tamer; Mary L Gemignani; Alexandra S Heerdt; Laurie Kirstein; Melissa Pilewskie; George Plitas; Virgilio S Sacchini; Lisa M Sclafani; Alice Ho; Hiram S Cody Journal: Ann Surg Date: 2017-09 Impact factor: 12.969
Authors: Kevin Kalinsky; William E Barlow; Julie R Gralow; Funda Meric-Bernstam; Kathy S Albain; Daniel F Hayes; Nancy U Lin; Edith A Perez; Lori J Goldstein; Stephen K L Chia; Sukhbinder Dhesy-Thind; Priya Rastogi; Emilio Alba; Suzette Delaloge; Miguel Martin; Catherine M Kelly; Manuel Ruiz-Borrego; Miguel Gil-Gil; Claudia H Arce-Salinas; Etienne G C Brain; Eun-Sook Lee; Jean-Yves Pierga; Begoña Bermejo; Manuel Ramos-Vazquez; Kyung-Hae Jung; Jean-Marc Ferrero; Anne F Schott; Steven Shak; Priyanka Sharma; Danika L Lew; Jieling Miao; Debasish Tripathy; Lajos Pusztai; Gabriel N Hortobagyi Journal: N Engl J Med Date: 2021-12-01 Impact factor: 91.245
Authors: Kathy S Albain; William E Barlow; Steven Shak; Gabriel N Hortobagyi; Robert B Livingston; I-Tien Yeh; Peter Ravdin; Roberto Bugarini; Frederick L Baehner; Nancy E Davidson; George W Sledge; Eric P Winer; Clifford Hudis; James N Ingle; Edith A Perez; Kathleen I Pritchard; Lois Shepherd; Julie R Gralow; Carl Yoshizawa; D Craig Allred; C Kent Osborne; Daniel F Hayes Journal: Lancet Oncol Date: 2009-12-10 Impact factor: 41.316
Authors: David N Krag; Stewart J Anderson; Thomas B Julian; Ann M Brown; Seth P Harlow; Takamaru Ashikaga; Donald L Weaver; Barbara J Miller; Lynne M Jalovec; Thomas G Frazier; R Dirk Noyes; André Robidoux; Hugh M C Scarth; Denise M Mammolito; David R McCready; Eleftherios P Mamounas; Joseph P Costantino; Norman Wolmark Journal: Lancet Oncol Date: 2007-10 Impact factor: 41.316
Authors: Armando E Giuliano; Karla V Ballman; Linda McCall; Peter D Beitsch; Meghan B Brennan; Pond R Kelemen; David W Ollila; Nora M Hansen; Pat W Whitworth; Peter W Blumencranz; A Marilyn Leitch; Sukamal Saha; Kelly K Hunt; Monica Morrow Journal: JAMA Date: 2017-09-12 Impact factor: 56.272
Authors: Joseph A Sparano; Robert J Gray; Della F Makower; Kathleen I Pritchard; Kathy S Albain; Daniel F Hayes; Charles E Geyer; Elizabeth C Dees; Matthew P Goetz; John A Olson; Tracy Lively; Sunil S Badve; Thomas J Saphner; Lynne I Wagner; Timothy J Whelan; Matthew J Ellis; Soonmyung Paik; William C Wood; Peter M Ravdin; Maccon M Keane; Henry L Gomez Moreno; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Adam M Brufsky; Deborah L Toppmeyer; Virginia G Kaklamani; Jeffrey L Berenberg; Jeffrey Abrams; George W Sledge Journal: N Engl J Med Date: 2018-06-03 Impact factor: 91.245
Authors: Mitch Dowsett; Jack Cuzick; Christopher Wale; John Forbes; Elizabeth A Mallon; Janine Salter; Emma Quinn; Anita Dunbier; Michael Baum; Aman Buzdar; Anthony Howell; Roberto Bugarini; Frederick L Baehner; Steven Shak Journal: J Clin Oncol Date: 2010-03-08 Impact factor: 44.544